Sacrifice of the intercostobrachial nerve (ICBN) during surgery is associated with development of persistent post-surgical pain (PPSP), which affects up to 60% of breast cancer surgery patients. A large, definitive trial is needed to establish whether nerve preservation techniques are effective in reducing post-surgical pain after breast cancer surgery. If the effect of ICBN preservation is consistent with observational studies, the absolute reduction of rates of persistent pain would be considerable.The primary objective is to determine the effect of ICBN preservation, versus usual care, on the prevalence and intensity of PPSP at one year after breast cancer surgery involving axillary lymph node dissection (ALND). Within the larger INSPIRE pilot, we will also be conducting a biomarker sub-study. The objectives of the biomarker sub-study are: 1) to determine the association between pro-inflammatory cytokine levels and the presence and intensity of persistent pain at 3 weeks, and 3 months post-surgery, and) 2) to determine the effect of study intervention on the change in cytokine levels (pre-operative to post-operative) in participants who consent to participate in the sub-study.
A 2016 systematic review that included 30 observational studies (n= 19,813 patients) found high quality evidence that axillary lymph node dissection (ALND) is associated with a 21% absolute risk increase of PPSP (95% CI = 13% to 29%). In many cases of breast cancer, surgery involves axillary approaches; however, preliminary evidence suggests that preservation of the intercostobrachial nerves (ICBN) may reduce the incidence of PPSP after axillary clearance. A 2014 systematic review found 3 small, single-center randomized controlled trials (RCTs), that enrolled a total of 309 patients, and explored the effect of ICBN preservation versus sacrifice during breast cancer surgery. This review found that division of the ICBN was associated with higher risk of sensory deficits, and that nerve preservation techniques increased the median operating time by 5 minutes. Due to limitations of existing evidence, clinical practice guidelines currently provide no recommendations on whether the ICBN should be preserved during axillary lymph node dissection.A large, definitive trial is needed to establish whether nerve preservation techniques are effective in reducing PPSP after breast cancer surgery involving ALND. If all the apparent effect of axillary dissection is associated with lack of ICBN preservation, the absolute reduction of rates of PPSP would be considerable. Furthermore, nerve sparing requires no specialized equipment, suggesting that scalability will be highly feasible. In addition, there is substantial evidence that neuro-inflammation as a result of neural damage leads to peripheral and central changes that can be described as peripheral and central sensitization, leading to PPSP. As such, we will be conducting a biomarker sub-study as part of the pilot program. Identification of biomarkers to correlate with the development of neuropathic pain may facilitate identification of individuals at risk for development of PPSP at an early stage. The INSPIRE trial provides an important opportunity to compare patients before and after nerve injury to further explore the association of persistent pain with cytokine biomarkers. The findings will improve our mechanistic understanding of PPSP.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Enrollment
50
For participants randomized to the ICBN preserving technique, surgeons will perform axillary dissection in which the second ICBN, just inferior to the axillary vein, will be preserved. Surgeons will be asked to indicate whether the ICBN nerve was fully preserved, partially preserved, or sacrificed. All study participants will receive anesthetic management at the discretion of the attending physician, which will be documented.
Juravinski Hospital
Hamilton, Ontario, Canada
RECRUITINGPersistent post-surgical pain (PPSP)
Post-surgery as defined by the World Health Organization (WHO). The WHO's definition requires 4 criteria for the diagnosis of PPSP: 1. Pain that began after surgery or a tissue trauma is experienced; 2. The pain is in an area of preceding surgery or tissue trauma, 3. The pain has persisted for at least three months after surgery, and 4. The pain is not better explained by an infection, malignancy, a pre-existing pain condition or any other alternative cause.
Time frame: 12 months
Moderate-to-severe PPSP
We will establish the severity of PPSP with an item from the Brief Pain Inventory Short Form (BPI-SF), which asks patients to report their 'average' pain intensity rating in the past 24 hrs, on a scale of 0 (no pain) to 10 (maximum pain). As per the BPI-SF scoring system, we will define moderate-to-severe pain as scores of ≥4 out of 10.
Time frame: 12 months
Biomarker Sub-Study: Cytokine Levels and PPSP
We will determine the correlation between pro-inflammatory cytokine levels and the presence and intensity of persistent pain at 3 weeks, and 3 months post-surgery
Time frame: 3 weeks, 3 months
Biomarker Sub-Study: Cytokine Levels Pre and Post-Op
We will determine the effect of the study intervention on the change in cytokine levels (pre-operative to post-operative) in participants who consent to participate in the sub-study.
Time frame: 3 weeks
Operative Time
Operative time will be measured from the time of the first incision until the time of closure of the incision.
Time frame: 12 months
General physical functioning
Short Form-36 Health Assessment Survey (SF-36) Physical Component Summary score. The range of possible scores goes from 0 (worst possible physical functioning) to 100 (best possible physical functioning)
Time frame: 12 months
General Mental functioning
Short Form-36 Health Assessment Survey (SF-36) Mental Component Summary score. The range of possible scores goes from 0 (worst possible mental functioning) to 100 (best possible mental functioning)
Time frame: 12 months
Upper limb-specific physical functioning
The Quick-Disability Arm Shoulder Hand Survey (Quick-DASH). An 11-item scale that measures physical function in people with any or multiple musculoskeletal disorders of the upper limb. The range of scores goes from 0 (worst possible functioning) to 100 (best possible functioning).
Time frame: 12 months
Return to Work
We will document when participants, who were employed before their surgery, return to work.
Time frame: 12 months
Adverse Events
All adverse events will be documented on the study specific case report forms. An independent medical monitor will also review each adverse event to determine its relatedness to the surgical treatment.
Time frame: 12 months
Pain Interference
Item PAININ18 of the PROMIS will be used to determine the proportion of patients who report somewhat-to-very much pain interference over 12 months post-surgery. This item is scored from 0 (not at all) to 4 (very much), and we will use a cut-off value of 2 (somewhat) or higher to define an event.
Time frame: 12 months
Use of Prescription Opioids
We will capture the proportion of patients who are prescribed an opioid at 3, 6, 9 and 12-months post-surgery, including the type and dose.
Time frame: 12 months
Return to household activities
We will document when participants return to their normal household activities.
Time frame: 12 months
Return to leisure activities
We will document when participants return to their normal leisure activities.
Time frame: 12 months
Return to pre-surgical functioning
We will document when participants achieve 80% of their pre-surgery function, as measured on a percentage scale of 0% (no function) to 100% (full pre-surgical function).
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.